Skip to main content
SpringerLink
Log in

Immunization as Treatment for Parkinson’s Disease

  • Chapter
  • First Online:
Birth, Life and Death of Dopaminergic Neurons in the Substantia Nigra

Part of the book series: Journal of Neural Transmission. Supplementa ((NEURALTRANS,volume 73))

Abstract

Parkinson’s disease and other neurodegenerative disorders share a common pathologic pathway with aggregation and deposition of misfolded proteins causing a disruption of particular neuronal networks. Several mechanisms have been implicated in the downstream events following deposition of misfolded proteins including free radical formation and failure of cellular defences such as autophagy or protein-degradation by the ubiquitin-proteasome pathway among many others. Treatments, however, capable of arresting or at least effectively modifying the course of disease do not yet exist. Recently, immunization approaches including passive and active immunization have been tested in animal models of various neurodegenerative disorders and have already entered into clinical trials for the treatment of Alzheimer’s disease. In this review, we specifically focus on the current status of immune-based approaches that are presently developed as a potential therapy of Parkinson’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

Aβ:

beta-Amyloid

CFA:

Complete Freund’s Adjuvant

GDNF:

Glial Cell-line derived Neurotrophic Factor

GFAP:

Glial fibrillary acidic protein

HE Stain:

Haematoxylin and Eosin Stain

Iba 1:

Ionized calcium-binding adaptor molecule 1

IHC:

Immunohistochemistry

LB:

Lewy Body

MPTP:

1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine

PD:

Parkinson’s disease

scFv:

Single chain variable Fragment

ThT:

Thioflavin T

UCH-L1:

Ubiquitin Carboxyl-terminal Esterase L1

References

  • Bainbridge J, Walker B (2003) Cell mediated immune responses against human prion protein. Clin Exp Immunol 133(3):310–317

    Article  CAS  PubMed  Google Scholar 

  • Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8):916–919

    Article  CAS  PubMed  Google Scholar 

  • Baxevanis CN, Perez SA, Papamichail M (2009) Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 58:317–324

    Article  PubMed  Google Scholar 

  • Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, Gorantla S, Nemachek C, Green SR, Przedborski S, Gendelman HE (2004) Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson’s disease. Proc Natl Acad Sci USA 101(25):9435–9440

    Article  CAS  PubMed  Google Scholar 

  • Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31:175–193

    Article  CAS  PubMed  Google Scholar 

  • Delavallee L, Assier E, Denys A, Falgarone G, Zagury JF, Muller S, Bessis N, Boissier MC (2008) Vaccination with cytokines in autoimmune diseases. Ann Med 40(5):343–351

    Article  CAS  PubMed  Google Scholar 

  • DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98(15):8850–8855

    Article  CAS  PubMed  Google Scholar 

  • Emadi S, Liu R, Yuan B, Schulz P, McAllister C, Lyubchenko Y, Messer A, Sierks MR (2004) Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 43(10):2871–2878

    Article  CAS  PubMed  Google Scholar 

  • Games D, Bard F, Grajeda H, Guido T, Khan K, Soriano F, Vasquez N, Wehner N, Johnson-Wood K, Yednock T, Seubert P, Schenk D (2000) Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1–42. Ann NY Acad Sci 920:274–284

    Article  CAS  PubMed  Google Scholar 

  • Gandhi S, Wood NW (2005) Molecular pathogenesis of Parkinson’s disease. Hum Mol Genet 14(18):2749–2755

    Article  Google Scholar 

  • Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64(9):1553–1562

    Article  CAS  PubMed  Google Scholar 

  • Lang AE, Lozano AM (1998) Parkinson’s disease. First of two parts. N Engl J Med 339(15):1044–1053

    Article  CAS  PubMed  Google Scholar 

  • Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Desai R, Hancock WW, Weiner HL, Selkoe DJ (2000) Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann NY Acad Sci 920: 328–331

    Article  CAS  PubMed  Google Scholar 

  • Luthi-Carter R (2003) Progress towards a vaccine for Huntington's disease. Mol Ther 7(5 Pt 1):569–570

    Article  CAS  PubMed  Google Scholar 

  • Maguire-Zeiss KA, Wang CI, Yehling E, Sullivan MA, Short DW, Su X, Gouzer G, Henricksen LA, Wuertzer CA, Federoff HJ (2006) Identification of human alpha-synuclein specific single chain antibodies. Biochem Biophys Res Commun 349(4):1198–1205

    Article  CAS  PubMed  Google Scholar 

  • Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 46(6):857–868

    Article  CAS  PubMed  Google Scholar 

  • Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287(5456): 1265–1269

    Article  CAS  PubMed  Google Scholar 

  • Miller TW, Messer A (2005) Intrabody applications in neurological disorders: progress and future prospects. Mol Ther 12(3):394–401

    Article  CAS  PubMed  Google Scholar 

  • Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408(6815):982–985

    Article  CAS  PubMed  Google Scholar 

  • Neff F, Wei X, Nölker C, Bacher M, Du Y, Dodel R. (2008) Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev. 7(6):501–507

    Google Scholar 

  • Olanow CW (2007) The pathogenesis of cell death in Parkinson’s disease–2007. Mov Disord 22 Suppl 17:S335–S342

    Article  PubMed  Google Scholar 

  • Olanow CW, Perl DP, DeMartino GN, McNaught KS (2004) Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 3(8):496–503

    Article  PubMed  Google Scholar 

  • Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, Papadimitriou A, Kalofoutis A, Buchman VL (2007) Autoantibodies to alpha-synuclein in inherited Parkinson’s disease. J Neurochem 101(3):749–756

    Article  CAS  PubMed  Google Scholar 

  • Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276(5321):2045–2047

    Article  CAS  PubMed  Google Scholar 

  • Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740):173–177

    Article  CAS  PubMed  Google Scholar 

  • Solomon B (2007) Clinical immunologic approaches for the treatment of Alzheimer's disease. Expert Opin Investig Drugs 16(6):819–828

    Article  CAS  PubMed  Google Scholar 

  • Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839–840

    Article  CAS  PubMed  Google Scholar 

  • Tofaris GK, Spillantini MG (2007) Physiological and pathological properties of alpha-synuclein. Cell Mol Life Sci 64(17):2194–2201

    Article  CAS  PubMed  Google Scholar 

  • Urushitani M, Ezzi SA, Julien JP (2007) Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 104(7): 2495–2500

    Article  CAS  PubMed  Google Scholar 

  • von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 15(4):473–490

    Article  Google Scholar 

  • Wakabayashi K, Tanji K, Mori F, Takahashi H (2007) The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27(5): 494–506

    Article  PubMed  Google Scholar 

  • Weintraub D, Comella CL, Horn S (2008) Parkinson’s disease – Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 14 2 Suppl:S40–S48

    PubMed  Google Scholar 

  • Wisniewski T, Sigurdsson EM (2007) Therapeutic approaches for prion and Alzheimer's diseases. FEBS J 274(15):3784–3798

    Article  CAS  PubMed  Google Scholar 

  • Zhou C, Emadi S, Sierks MR, Messer A (2004) A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther 10(6):1023–1031

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Philipps-University Marburg, Rudolf-Bultmann-Straße 8, 35039, Marburg, Germany

    Daniela Besong Agbo, Frauke Neff, Florian Seitz, Christian Binder, Wolfgang H. Oertel, Michael Bacher & Richard Dodel

Authors
  1. Daniela Besong Agbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frauke Neff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Florian Seitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christian Binder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wolfgang H. Oertel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael Bacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Richard Dodel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Dodel .

Editor information

Editors and Affiliations

  1. Fac. Medicina e Chirurgia, Università di Palermo, Corso Tukory 129, Palermo, 90134, Italy

    Giuseppe Giovanni

  2. Mario Negri, Istituto di Ricerche Farmacologiche, Via Nazionale 8, Santa Maria Imbaro, 66030, Italy

    Vincenzo Di Matteo

  3. Mario Negri, Istituto di Ricerche Farmacologiche, Via Nazionale 8, Santa Maria Imbaro, 66030, Italy

    Ennio Esposito

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag/Wien Printed in Germany

About this chapter

Cite this chapter

Agbo, D.B. et al. (2009). Immunization as Treatment for Parkinson’s Disease. In: Giovanni, G., Di Matteo, V., Esposito, E. (eds) Birth, Life and Death of Dopaminergic Neurons in the Substantia Nigra. Journal of Neural Transmission. Supplementa, vol 73. Springer, Vienna. https://doi.org/10.1007/978-3-211-92660-4_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-92660-4_26

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-92659-8

  • Online ISBN: 978-3-211-92660-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation